| Catalog No. |
TD-HY355036 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
Fab-G1-kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
CD41, ITGAB, GPIIb, ITGA2B, Platelet membrane glycoprotein IIb, GP2B, Integrin alpha-IIb, GPalpha IIb, GPIIIa, Integrin beta-3, CD61, ITGB3, Platelet membrane glycoprotein IIIa, GP3A |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P08514 & P05106 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
C4G1,YM-337,CAS:339086-80-5 |
| Background |
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |